Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 6;2(2):100152. doi: 10.1016/j.xops.2022.100152

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the American Academy of Ophthalmology.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

CONSORT diagram. Among the 223 patients, 202 cases of treatment-naive non-neovascular chronic central serous chorioretinopathy (cCSC) were identified by excluding 16 patients with a treatment history and 5 patients with macular neovascularization (MNV). After excluding patients who underwent other treatments such as photocoagulation and anti-VEGF therapy (n = 44), and those who underwent cataract surgery during observation (n = 3), 74 eyes of 74 patients who underwent reduced-fluence photodynamic therapy (rf-PDT) and 81 eyes of 81 control patients were analyzed. ∗History of ocular treatment: history of photocoagulation, anti-VEGF therapy, photodynamic therapy, or any other ocular surgery except for cataract surgery.